Arch Therapeutics, Inc. (OTCMKTS:ARTH) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.
Other analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Arch Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of Arch Therapeutics in a research note on Monday, September 18th. Finally, Ifs Securities reissued an “outperform” rating on shares of Arch Therapeutics in a research note on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Arch Therapeutics has an average rating of “Buy” and a consensus price target of $2.31.
Shares of Arch Therapeutics (OTCMKTS ARTH) opened at $0.59 on Friday. Arch Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $0.89.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
Receive News & Ratings for Arch Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.